衣原体纳米疫苗的研究进展  

Research progress in Chlamydia nanovaccines

作　　者：谢丽娟 谢小平[2] 孙珍洁 陆春雪[1] XIE Li-juan;XIE Xiao-ping;SUN Zhen-jie;LU Chun-xue(Institution of Pathogenic Biology,University of South China,Hengyang 421001,China;The First Affiliated Hospital of University of South China,Hengyang 421001,China)

机构地区：[1]南华大学病原生物学研究所,衡阳421001 [2]南华大学附属第一医院,衡阳421001

出　　处：《中国人兽共患病学报》2022年第1期48-54,61,共8页Chinese Journal of Zoonoses

基　　金：国家自然科学基金(No.81471969);湖南省教育厅创新平台开放基金(No.20K108)联合资助。

摘　　要：衣原体疫苗接种的最终目的是刺激机体体液免疫、细胞免疫及黏膜免疫应答的有机结合,以发挥抗感染保护作用、减少炎症病理的形成。衣原体抗原成分单独接种或与佐剂联合应用均不能全面激发机体的免疫应答。纳米粒子因具有降低毒副作用、靶向输送、缓释、避免被酶降解、提高活性和稳定性等独特优势,为衣原体疫苗设计提供了新策略。应用于医学领域的纳米材料种类繁多,衣原体纳米疫苗已取得一定程度的进展,本文主要对纳米粒子脂质体和多聚体微粒在衣原体疫苗中的研究进展作简要概述。The ultimate goal of Chlamydia vaccination is to stimulate a combination of humoral,cellular and mucosal immune responses to exert anti-infective protection and decrease the formation of inflammatory pathology.Chlamydia antigen components,alone or in combination with adjuvants,cannot fully stimulate the immune response.However,nanoparticles offer new strategies for chlamydial vaccine design,owing to their unique advantages such as less toxicity,targeted delivery,slow release,resistance to degradation by enzymes,and improved activity and stability.A wide variety of nanomaterials have been applied in the medical field,and some progress has been made in the development of chlamydial nanovaccines.This article provides a brief overview of research progress in the use of liposome nanoparticles and multimeric particles in chlamydial vaccines.

关 键 词：衣原体 纳米疫苗 脂质体 多聚体微粒 

分 类 号：R374[医药卫生—病原生物学]